Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
about
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral BloodStem cell technology in breast cancer: current status and potential applicationsCirculating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A reviewClinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsCirculating tumors cells as biomarkers: progress toward biomarker qualificationProgress in circulating tumor cell capture and analysis: implications for cancer managementSingle cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesHER2-positive circulating tumor cells in breast cancerThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status.Analysis of circulating tumor cells in breast cancer.Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells.Circulating tumor cells: from bench to bedsideSingle circulating tumor cell profiling: a new perspective for targeted therapy?A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease.Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progressionCirculating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinomaDetection of HER2 amplification in circulating free DNA in patients with breast cancer.Preoperative serum HER2 extracellular domain levels in primary invasive breast cancerMay CTC technologies promote better cancer management?Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkCirculating tumour cells: their utility in cancer management and predicting outcomes.Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinomaBreast Cancer Update 2014 - Focus on the Patient and the Tumour.Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.Molecular profiling of individual tumor cells by hyperspectral microscopic imagingComparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways?A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevanceCirculating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.Serum HER2 levels determined by two methods in patients with metastatic breast cancer.Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications.
P2860
Q24597444-C751366D-F211-4596-8B4C-CE183C2BFED5Q26746223-08DE9CF1-C626-4F27-8177-CBCED20AC128Q26752116-6E37EC2F-AFC2-4FAA-B075-ED2D8C1D2F20Q26827936-EF282E62-3D46-4F54-A641-8766F86A62EFQ26852579-77EE46D8-4F89-4AE9-957F-662BE51F41F9Q27025737-E0711D20-B467-43CA-A9FE-630E4263A9C0Q28483475-CE2C6A16-07D5-4826-9F95-CC39BCF141E3Q33802925-6B062832-C460-401A-9569-DD6538CE8C16Q33815087-613ACE53-130E-4250-A1FF-C3F37B34CF02Q33820233-66D6E489-84EE-4BCF-99FC-70982DB41491Q33927261-1B5D9737-08F6-4D0F-A51E-60858E71CC71Q34156275-58AA6925-FF4F-4D04-A151-F300030B4202Q34256705-3725E5F9-83B0-4486-9113-86B965881C08Q34307782-45F6B28E-5956-4D60-B5DD-4816B0289BBAQ34468264-2496B6BA-5F87-4265-9EB4-70886CE1A81FQ34486941-B0E92B31-95EB-49CE-973D-FF6885337210Q34496964-58149010-4AD6-40BE-AD57-A8501F111657Q34687153-110FFF33-A2B1-41CD-B126-8B8158A6322FQ34730478-A4B2C0B3-B8E5-4D59-9D68-7D291D71B1B0Q34806810-EF18C255-9FEB-427D-AD59-0AFD77D21423Q34967515-5D563FD5-E67E-43E3-808D-543EBCD93E54Q35016353-A7B30A13-5809-4757-95AB-DE4D0B01699AQ35054455-089F6C99-71E9-4F99-BE34-A05F23C0293AQ35076325-50C1E093-C202-4DBB-AD66-5CCE363839F5Q35161280-67F1F9CF-129B-48C5-A275-6C7A17F1FC79Q35180940-DAECEBC7-9879-41D8-B6B4-5A63839A158EQ35665814-ED99CB3A-C9DA-48C6-8026-7F021EE5B4F7Q35913941-11731457-93B1-4CE5-B889-F2BB17DA8B01Q36085375-349D9001-E83D-4E16-AE6E-457ED02A5098Q36175119-2189F793-C48D-4CF9-84EC-96B6D182B3CEQ36730394-E1F9AFFD-B35A-48C7-ACB7-08B870FAC3A3Q36804888-270E80AD-61FE-4A8B-AA47-51594564801AQ37019257-4954F242-9223-418F-AD20-BCC7D35F03FAQ37218987-44A977F2-C353-46F6-8152-CD07A51BCAC8Q37352090-BD0AEC02-0162-40D3-AF42-873CCEB90F32Q37360176-3C124A5C-A7DD-4496-BDA8-8582AF8AB211Q37360230-E1C774D9-0A7F-40C0-97A1-662E4BCA560EQ37386179-E00CA04D-6939-44FB-801D-D9754C4AB359Q37386272-0F923C0D-120B-4687-95F1-FA0A55B35121Q37626062-019D5B6B-F788-423A-8C10-4C922C18F54E
P2860
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Determination of HER2 status u ...... tive or of unknown HER2 status
@ast
Determination of HER2 status u ...... tive or of unknown HER2 status
@en
type
label
Determination of HER2 status u ...... tive or of unknown HER2 status
@ast
Determination of HER2 status u ...... tive or of unknown HER2 status
@en
prefLabel
Determination of HER2 status u ...... tive or of unknown HER2 status
@ast
Determination of HER2 status u ...... tive or of unknown HER2 status
@en
P2093
P2860
P356
P1476
Determination of HER2 status u ...... tive or of unknown HER2 status
@en
P2093
Erich Solomayer
Jonathan Uhr
Karl Sotlar
Nancy Lane
Silke Duerr-Stoerzer
Sven Becker
Volkmar Mueller
P2860
P2888
P356
10.1186/BCR1783
P577
2007-01-01T00:00:00Z
P5875
P6179
1006682249